Clinical Trials for Mesothelioma Patients—A Study of Azacitidine in combination with Temo/Azac: Exclusion Criteria

Read the exclusion criteria for a current clinical trial about the use of a Phase I dose study of Azacitidine in combination with Temo/Azac for patients with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.

Exclusion Criteria:

§           Known or suspected hypersensitivity to azacitidine or mannitol

§           Pregnant or breast-feeding

§           Histology other than soft-tissue sarcoma or mesothelioma

§           Active or uncontrolled infection or other serious systemic disease

§           Prior treatment with temozolomide or azacitidine

§           Pregnant or lactating women

§           Uncontrolled central nervous system metastases

§           Liver metastases

§           Patients will not be excluded if they do not wish to participate in the second biopsy for tissue evaluation

§           Subjects who have not had prior chemotherapy.

Courtesy of ClinicalTrials.gov, a service of the U.S. National Institutes of Health

If you or a loved one has been diagnosed with an Asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading Asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.